Updates on Treatment of Gemcitabine-Refractory Pancreatic Adenocarcinoma

被引：0
|
作者：
Makrilia, Nektaria [1 ]
Syrigos, Kostas N. [1 ]
Saif, Muhammad W. [2 ,3 ]
机构：
[1] Sotiria Gen Hosp, Athens Med School, Dept Med 3, Oncol Unit, Athens, Greece
[2] Columbia Univ Coll Phys & Surg, 177 Ft Washington Ave,Suite 6-435, New York, NY 10032 USA
[3] New York Presbyterian Hosp, Pancreas Ctr, New York, NY USA
来源：
JOURNAL OF THE PANCREAS | 2011年 / 12卷 / 04期
关键词：
capecitabine; lapatinib; Pancreatic Neoplasms; S-1; Treatment Failure;
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Gemcitabine monotherapy and gemcitabine-based regimens are the current standard of care for locally advanced or metastatic pancreatic adenocarcinoma. However, there is still great controversy over the role of salvage chemotherapy after failure of gemcitabine. This review is an update on the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting regarding the most important developments in the treatment of refractory pancreatic cancer, as they were reported in Abstracts #e14542 and #e14588.
引用
收藏
页码：351 / 354
页数：4
相关论文
共 50 条
  • [21] Weekly docetaxel as salvage therapy in patients with gemcitabine-refractory metastatic pancreatic cancer
    Cereda, S.
    Reni, M.
    JOURNAL OF CHEMOTHERAPY, 2008, 20 (04) : 509 - 512
  • [22] A dose-escalation study of gemcitabine (Gem) plus oxaliplatin (Ox) in combination with imatinib in patients (pts) with gemcitabine-refractory advanced pancreatic adenocarcinoma (PC)
    Starling, N.
    Hawkes, E. A.
    Chau, I.
    Watkins, D. J.
    Thomas, J.
    Webb, J.
    Brown, G.
    Thomas, K.
    Oates, J. R.
    Cunningham, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [23] Phase II trial of metformin and paclitaxel for patients with gemcitabine-refractory advanced adenocarcinoma of the pancreas
    Braghiroli, Maria Ignez
    de Celis Ferrari, Anezka C. R.
    Pfiffer, Tulio Eduardo
    Alex, Alexandra Kichfy
    Nebuloni, Daniela
    Carneiro, Allyne S.
    Caparelli, Fernanda
    Senna, Luiz
    Lobo, Juliana
    Hoff, Paulo Marcelo
    Riechelmann, Rachel P.
    ECANCERMEDICALSCIENCE, 2015, 9
  • [24] Phase II trial of inetforrnin and paclitaxel for patients with gemcitabine-refractory advanced adenocarcinoma of the pancreas
    Rubin De Celia Ferrari, Anezlca Carvalho
    Flesch Pfiffer, Tulio Eduardo
    Alex, Alexandra Khichfy
    Nebulonl, Danielle R.
    Carnelro, Allyne Q.
    Caparell, Fernanda Cunha
    Senna Leite, Luiz Antonio
    Freitas Meiro Braghiroli, Maria Ignez
    Lobo, Juliana
    Hoff, Paulo Marcelo
    Riechelmann, Rachel Pimenta
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [25] Liposomal irinotecan in gemcitabine-refractory metastatic pancreatic cancer: efficacy, safety and place in therapy
    Kipps, Emma
    Young, Kate
    Starling, Naureen
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2017, 9 (03) : 159 - 170
  • [26] Prognostic factors and prognostic index for chemonaive and gemcitabine-refractory patients with advanced pancreatic cancer
    Marechal, R.
    Demols, A.
    Gay, F.
    De Maertelaere, V.
    Arvanitaki, M.
    Hendlisz, A.
    Van Laethem, J. L.
    ONCOLOGY, 2007, 73 (1-2) : 41 - 51
  • [27] A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer
    Ko, Andrew H.
    Venook, Alan P.
    Bergsland, Emily K.
    Kelley, R. Kate
    Korn, W. Michael
    Dito, Elizabeth
    Schillinger, Brian
    Scott, Janet
    Hwang, Jimmy
    Tempero, Margaret A.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 66 (06) : 1051 - 1057
  • [28] A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer
    Andrew H. Ko
    Alan P. Venook
    Emily K. Bergsland
    R. Kate Kelley
    W. Michael Korn
    Elizabeth Dito
    Brian Schillinger
    Janet Scott
    Jimmy Hwang
    Margaret A. Tempero
    Cancer Chemotherapy and Pharmacology, 2010, 66 : 1051 - 1057
  • [29] A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer
    Morizane, Chigusa
    Okusaka, Takuji
    Furuse, Junji
    Ishii, Hiroshi
    Ueno, Hideki
    Ikeda, Masafumi
    Nakachi, Kohei
    Najima, Mina
    Ogura, Takashi
    Suzuki, Eiichiro
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 63 (02) : 313 - 319
  • [30] A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer
    Chigusa Morizane
    Takuji Okusaka
    Junji Furuse
    Hiroshi Ishii
    Hideki Ueno
    Masafumi Ikeda
    Kohei Nakachi
    Mina Najima
    Takashi Ogura
    Eiichiro Suzuki
    Cancer Chemotherapy and Pharmacology, 2009, 63 : 313 - 319
12345